全文获取类型
收费全文 | 503篇 |
免费 | 16篇 |
国内免费 | 9篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 67篇 |
口腔科学 | 1篇 |
临床医学 | 33篇 |
内科学 | 218篇 |
皮肤病学 | 1篇 |
神经病学 | 28篇 |
特种医学 | 3篇 |
外科学 | 30篇 |
综合类 | 40篇 |
预防医学 | 19篇 |
药学 | 68篇 |
中国医学 | 2篇 |
肿瘤学 | 13篇 |
出版年
2023年 | 9篇 |
2022年 | 14篇 |
2021年 | 26篇 |
2020年 | 24篇 |
2019年 | 23篇 |
2018年 | 32篇 |
2017年 | 17篇 |
2016年 | 32篇 |
2015年 | 14篇 |
2014年 | 66篇 |
2013年 | 48篇 |
2012年 | 27篇 |
2011年 | 32篇 |
2010年 | 18篇 |
2009年 | 21篇 |
2008年 | 30篇 |
2007年 | 29篇 |
2006年 | 22篇 |
2005年 | 28篇 |
2004年 | 5篇 |
2003年 | 6篇 |
2002年 | 2篇 |
2001年 | 2篇 |
1993年 | 1篇 |
排序方式: 共有528条查询结果,搜索用时 62 毫秒
521.
目的:探讨血清抑制素B对卵巢储备功能预测的临床价值。方法:选择月经周期正常,年龄25-35岁的健康女性30例作为正常组;选择绝经过渡期,年龄40-50岁,有不同程度围绝经期综合征症状的女性36例作为研究组;检测月经第3天血清中抑制素B水平、E2水平及FSH水平。结果:研究组妇女血清中抑制素B水平下降,与正常组妇女比较,差异有统计学意义(P〈0.01);FSH水平升高,但差异无统计学意义(P〉0.05);E2水平升高,但差异无统计学意义(P〉0.05)。结论:血清抑制素B水平下降是反映卵巢储备功能下降的直接指标,对预测卵巢储备功能具有一定的临床价值,可帮助诊断卵巢功能衰退。 相似文献
522.
《Journal of vascular surgery》2023,77(1):158-169.e8
ObjectiveStatin therapy is the standard of care for patients with carotid artery stenosis given its proven cardiovascular benefits. However, the impact of statin therapy on outcomes in patients undergoing carotid revascularization in the Vascular Quality Initiative has not yet been evaluated. Therefore, our aim was to investigate the association of statin therapy with outcomes following carotid endarterectomy (CEA), transfemoral carotid artery stenting (tfCAS), and transcarotid artery revascularization (TCAR).MethodsWe identified all patients who underwent CEA, tfCAS, or TCAR in the Vascular Quality Initiative registry from January 2016 to September 2021. To compare outcomes, we stratified patients by procedure type and created 1:1 propensity score-matched cohorts of patients who received no preoperative statin therapy (within 36 hours of procedure) versus those who received preoperative statin therapy. Propensity scores incorporated demographic characteristics, comorbidities, carotid symptom status, preoperative medications, and physician and hospital procedural experience. The primary outcome was a composite end point of in-hospital stroke and/or death. As a secondary analysis, we performed repeat propensity score-matching by postoperative statin use (prescribed at discharge) and assessed 5-year mortality. Relative risks (RR) and hazard ratios (HR) were calculated using log binomial regression and Cox regression, respectively.ResultsAmong 97,835 CEA, 20,303 tfCAS, and 22,371 TCAR patients, 15%, 17%, and 10% of patients did not receive preoperative statin therapy, respectively. Compared with statin use, no statin use was associated with a higher risk of in-hospital stroke or death among 13,434 matched CEA patients (no statin, 1.7% vs statin, 1.4%; RR, 1.2; 95% confidence interval [CI], 1.02-1.5) and among 2707 matched tfCAS patients (4.8% vs 2.8%; RR, 1.7; 95% CI, 1.3-2.3). However, there was no difference for this outcome by statin use among 2089 matched TCAR patients (1.8% vs 1.6%; RR, 1.1; 95% CI, 0.7-1.8). At 5 years, no statin therapy at discharge was associated with higher 5-year mortality after CEA (15% vs 10%; HR, 1.8; 95% CI, 1.6-2) and tfCAS (18% vs 14%; HR, 1.5; 95% CI, 1.2-1.8), but there was no difference after TCAR (14% vs 11%; HR, 1.3; 95% CI, 0.9-1.8).ConclusionsCompared with statin use, no statin use was associated with a higher risk of in-hospital stroke or death and 5-year mortality among CEA and tfCAS patients. Although there was no significant difference in outcomes among TCAR patients, this may in part be due to lower statistical power in this cohort. Overall, statin therapy is essential in the short- and long-term management of patients undergoing carotid revascularization. Our findings not only support current Society for Vascular Surgery recommendations for statin therapy in patients undergoing carotid revascularization, but they also highlight an important opportunity for quality improvement. 相似文献
523.
524.
525.
526.
527.
《Journal of thoracic oncology》2023,18(8):1082-1093
IntroductionTo determine the effect of statin use during concurrent chemoradiotherapy (CCRT) on overall survival and esophageal squamous cell carcinoma (ESCC)-specific survival in patients with ESCC receiving standard CCRT.MethodsIn this propensity score-matching cohort study, we used data from the Taiwan Cancer Registry Database and National Health Insurance Research Database to investigate the effects of statin use during the period of CCRT on overall survival and ESCC-specific survival.ResultsStatin use during the period of CCRT was found to be a considerable and independent prognostic factor for overall survival and ESCC-specific survival. The adjusted hazard ratio (aHR) for all-cause mortality in the statin group compared with that of the non-statin group was 0.65 (95% confidence interval: 0.51–0.84, p = 0.0009). The aHR for ESCC-specific mortality in the statin group compared with that of the non-statin group was 0.63 (95% confidence interval: 0.47–0.84, p = 0.0016). The use of hydrophilic statins such as rosuvastatin and pravastatin was associated with the greatest survival benefits. A dose-response relationship was also found, with higher cumulative defined daily doses and higher daily intensity of statin use associated with lower mortality.ConclusionsThis study is the first to reveal that statin use during the period of CCRT for ESCC is associated with improvement in overall survival and ESCC-specific survival. In addition, we found that use of rosuvastatin, pravastatin, and simvastatin was associated with better survival outcomes for patients with ESCC receiving CCRT. Furthermore, we found a dose-response relationship of statin use associated with lower ESCC-specific mortality. 相似文献
528.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2023,33(5):1087-1092
Background and aimsIn observational studies, statins have been suggested to have protective effects on venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). To this aim, we performed a two-sample mendelian randomization (MR) analysis to determine whether these associations were causal.Methods and resultsData on the single nucleotide polymorphisms (SNPs) related to statin medication were obtained from the FinnGen study, and data for VTE, PE and DVT of lower extremities (LEDVT) were from the UK Biobank study, respectively. Inverse variance weighted (IVW) method was used as the principal analysis of MR, and sensitivity analysis was performed to detect horizontal pleiotropy and heterogeneity. MR estimates showed an inverse causal association between statin medication and the risk of VTE (odds ratio [OR]: 0.999, 95% CI: 0.998–1.000, P = 0.004), PE (OR: 0.999, 95% CI: 0.999–1.000, P = 0.011) and LEDVT (OR: 0.999, 95% CI: 0.999–1.000, P = 0.008).ConclusionOur findings provide direct evidence that statins might decrease the risk of VTE, PE and LEDVT in agreement with observational studies. The specific mechanism of statin therapy for venous thromboembolism needs to be further studied. 相似文献